Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.70 |
| ▸ | CASP7 | P55210 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.59 |
| ▸ | TYMS | P04818 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30513596 | 1.00 | CASP1 (0.70) | CASP1CASP7HSD17B10PBRM1TYMS | |
| Hydrochloric Acid SCHEMBL3873080 | 0.98 | CASP1 (0.68) | CASP1CASP7HSD17B10PBRM1TYMS | |
| SCHEMBL656011 | 0.88 | CASP1 (0.55) | CASP1CASP7HSD17B10PBRM1TYMS | |
| SCHEMBL30067461 | 0.88 | CASP1 (0.55) | CASP1CASP7HSD17B10PBRM1TYMS | |
| SCHEMBL4878376 | 0.88 | CASP1 (0.55) | CASP1CASP7HSD17B10PBRM1TYMS | |
| SCHEMBL16559372 | 0.84 | CASP1 (0.55) | CASP1CASP7HSD17B10PBRM1TYMS | |
| SCHEMBL434358 | 0.83 | CASP1 (1.00) | CASP1CASP7HSD17B10PBRM1CA9 | |
| Hydrochloric Acid SCHEMBL27821207 | 0.81 | CASP1 (0.96) | CASP1CASP7HSD17B10PBRM1CA9 | |
| SCHEMBL3278777 | 0.80 | MAPT (0.54) | CASP1CASP7HSD17B10TYMSCA9 | |
| SCHEMBL6362924 | 0.80 | CASP1 (0.47) | CASP1CASP7HSD17B10PBRM1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108822550-B | Preparation method of novel liquid crystal elastomer material | 浙江鑫都文化用品股份有限公司 | 2021-06-04 | — | — | CN | claimed |
| CN-108893139-A | A kind of method of use amphipathic catalyst fuel desulfuration containing neodymium | 李成霞 | 2018-11-27 | — | — | CN | claimed |
| CN-108864030-A | A method of carbon dioxide synthesizing annular carbonate is catalyzed with new catalyst | 宁波高新区诠宝绶新材料科技有限公司 | 2018-11-23 | — | — | CN | claimed |
| CN-108863800-A | A method of using magnetic Er ions catalyst preparation 4- fluorine biphenyl-4-carboxylic acid ester | 孝感寰誉新材科技有限公司 | 2018-11-23 | — | — | CN | claimed |
| CN-108841379-A | A kind of preparation method of the OLED hole transport new material suitable for solution processing | 刘坤 | 2018-11-20 | — | — | CN | claimed |
| CN-108822550-A | A kind of preparation method of liquid crystal elastic body new material | 王琪宇 | 2018-11-16 | — | — | CN | claimed |
| WO-2009135925-A1 | SUBSTITUTED N-IMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-11-12 | — | — | WO | claimed |
| WO-2009135927-A1 | SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-11-12 | — | — | WO | claimed |
| EP-2116547-A1 | Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-11 | — | — | EP | claimed |
| EP-2116546-A1 | Substituted N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-HT6 ligands | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-11 | — | — | EP | claimed |
| US-20090163547-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-25 | — | — | US | claimed |
| EP-1960343-A2 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios del Dr. Esteve S.A. (ES) | 2008-08-27 | — | — | EP | claimed |
| WO-2007054257-A2 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-18 | — | — | WO | claimed |
| US-12441679-B2 | Acrylamide-substituted indane compounds and therapeutic use thereof | SANOFI (FR) | 2025-10-14 | — | — | US | disclosed |
| CN-119462458-A | Covalent inhibitor of targeted hCES A and preparation method and application thereof | 中国人民解放军海军军医大学 | 2025-02-18 | — | — | CN | disclosed |
| CN-116057042-B | Acrylamide-substituted indane compounds and their therapeutic uses | 赛诺菲 | 2024-10-18 | — | — | CN | disclosed |
| US-5563136-A | ADMINISTERING FOR GASTROINTESTINAL OR NERVOUS SYSTEM DISORDERS CONNECTED WITH CHOLECYSTOKININ AND GASTRIN | RHONE-POULENC RORER S.A. (FR) | 1996-10-08 | — | — | US | disclosed |
| WO-1996019440-A1 | ACETAMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS FOR THE NITRIC OXIDE SYNTHASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-06-27 | — | — | WO | disclosed |
| EP-0275131-B1 | HERBICIDAL OXOINDANES AND TETRAHYDRONAPHTHALENES | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1992-09-23 | — | — | EP | disclosed |
| EP-0275131-A1 | Herbicidal oxoindanes and tetrahydronaphthalenes | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1988-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441679-B2 | Acrylamide-substituted indane compounds and therapeutic use thereof | IDH2, INA, IDH3A | CASP1 1665/4885CASP7 1053/4885HSD17B10 1658/4885 |
| US-20090163547-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | HTR6, HTR5A, HTR1A | CASP1 3330/4885CASP7 3332/4885HSD17B10 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.